Does ICER’s Psoriasis Drug Valuation Undercut Routine Step Therapy?

Institute for Clinical and Economic Review issues final cost effectiveness report on psoriasis agents that improves the value rating earlier assigned to novel treatments based on a consideration of actual net prices. Paid subscription required to read more. (Source: Cathy Kelly, Pink Sheet, 12/9/16)

You might also be interested in:

ICER’s Updated Assessment of New Targeted Therapies for… June 13, 2018
More on ICER’s New Transparency Pilot April 14, 2018
ICER Releases Updated Report on Targeted Treatments for Plaque… August 5, 2018
ICER Releases Report on Plaque Psoriasis Treatments April 28, 2018
ICER Report Highlights Antiandrogen Therapies for Early-State… October 4, 2018
ICER Final Report: Voretigene Neparvovec Provides Long-Term Value February 18, 2018
Task Force’s Recommendations Could Impact Payers, Sponsors November 2, 2017